BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trialBNC210 Phase 2b PTSD trial on target for start in mid-2021 with final ...
ADELAIDE, Australia--(BUSINESS WIRE)--Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, announces that an additional data analysis conducted in Sweden by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback